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Given the continued interest in deﬁning the optimal management of individuals
with type 2 diabetes, the Editor of Diabetes Care convened a working party of
diabetes specialists to examine this topic in the context of insulin therapy. This
was prompted by recent new evidence on the use of insulin in such people. The
group was aware of evidence that the beneﬁts of insulin therapy are still usually
offered late, and thus the aim of the discussion was how to deﬁne the optimal
timing and basis for decisions regarding insulin and to apply these concepts in
practice. It was noted that recent evidence had built upon that of the previous
decades, together conﬁrming the beneﬁts and safety of insulin therapy, albeit
with concerns about the potential for hypoglycemia and gain in body weight.
Insulin offers a unique ability to control hyperglycemia, being used from the time
of diagnosis in some circumstances, when metabolic control is disturbed by medical
illness, procedures, or therapy, as well as in the longer term in ambulatory care. For
those previously starting insulin, various other forms of therapy can be added later,
which offer complementary effects appropriate to individual needs. Here we review
current evidence and circumstances in which insulin can be used, consider individ-
ualized choices of alternatives and combination regimens, and offer some guidance
on personalized targets and tactics for glycemic control in type 2 diabetes.
The ultimate goal of diabetes management is prevention of long-term complica-
tions. An important means to this end is improvement andmaintenance of glycemic
control over time. Unfortunately, this is not a simple task due to the progressive
nature of the disease, which requires timely optimization of treatment, leading in a
majority of cases to insulin therapy. Various forces oppose and thus delay starting
insulin, and the lag between the time insulin is needed and the time it is used has
been described as due to “clinical inertia” (1). Shah et al. (2) have reported that less
than one-half of patients with high HbA1c levels have their treatment optimized
even when specialists manage their condition. However, in that study, specialists
weremore active in prescribing insulin than primary care physicians. Nonetheless, in
all areas of clinical practice, use of insulin tends to be delayed and irreversible
complications can already be present by the time it is started. In a multinational
survey involving.66,000 diabetic patients, average HbA1c at the time of beginning
insulin was 80 mmol/mol (9.5%) and ;90% of the participants already had some
kind of complication (3). Various concerns serve as barriers to starting insulin, and
often it is a physician rather than the patient who decides to postpone insulin
therapy (4).
The speciﬁc point at which insulin therapy should begin can be difﬁcult to deﬁne
for an individual person, and universal guidance has proved elusive. Type 2 diabetes is
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characterized by progressive b-cell
(b-cell) failure, but the natural history
of b-cell decline is variable and assess-
ment of b-cell function is difﬁcult. Be-
yond the problem of assessing the
need for insulin, exogenous insulin has
potential effects that frequently worry
both people with diabetes and health
care professionals (4). These include hy-
poglycemia and weight gain. Fear of in-
jections themselves and various negative
connotations of insulin therapy, such as
advanced disease and personal failure,
also pose signiﬁcant hurdles for some
people despite modern injection devices.
However, suggestion of a need to in-
crease self-monitoring, and thus ﬁnger
pricking, to support optimization of insu-
lin have ameliorated injection problems
to some degree. Finally, educational sup-
port for starting injections and adjusting
thedosage of insulin is not easily available
to all people.
GROWING EVIDENCE FOR INSULIN
THERAPY
As noted above, a commonly accepted
view is that type 2 diabetes develops
when insulin secretion can no longer
compensate for the underlying meta-
bolic disturbance. As secretory capacity
progressively declines with time (5), it is
understood that most people with type
2 diabetes will eventually require insulin
therapy. Increasing use of therapies to
protect against cardiovascular disease is
extending the life of people with diabe-
tes (6), and consequently more people
will come to need insulin therapy. Diag-
nosis at a younger age will also extend
the time of active treatment of diabetes.
The effect of use of insulin in type 2 di-
abetes from the time of diagnosis has
been evaluated in clinical trials, notably
the UK Prospective Diabetes Study
(UKPDS) and Outcome Reduction With
Initial Glargine Intervention (ORIGIN)
(7–9). UKPDS showed that early and
continued glucose control can reduce
microvascular complications and, in
the long-term, improve cardiovascular
prognosis (7,10). The beneﬁcial effect
of insulin therapy is further supported
by studies in type 1 diabetes where it
is apparent that if insulin therapy is
used effectively to induce early glycemic
control, both micro- and macrovascular
protection is achieved (11). Although it
is acknowledged that achieving HbA1c
,53 mmol/mol (7.0%) is a difﬁcult
task, improvement of glycemic control
with insulin is associated with improved
patient well-being even if the HbA1c tar-
get is not achieved (12) (Table 1).
Short-term studies comparing insu-
lins show that a high percentage of peo-
ple with established type 2 diabetes not
well controlled with oral therapies can
achieve blood glucose control to target,
and without high rates of hypoglycemia
(13–15). Further, with optimization of
dosage and timing, such control can be
maintained for least 3 years, with hypo-
glycemia rates constant at;10% of peo-
ple with an event in a year (16).
Observational studies show that in rou-
tine practice, HbA1c of ;57 mmol/mol
(7.4%) is achievedwith little hypoglycemia
in diverse countries around the world
(3,17). Most recently, the ORIGIN trial
introduced insulin therapy in people
with relatively short-duration type 2 di-
abetes and high cardiovascular risk (9).
With continuation of prior oral therapy
and systematic titration of basal insulin
(glargine), fasting glucose was kept at
normal levels (,5.3 mmol/L) and me-
dian HbA1c #45 mmol/mol (6.3%) for
.6 years. Systematically intensiﬁed
oral therapy, the comparator regimen
in ORIGIN, also maintained very good
control during this time. This study
showed that despite maintaining very
good glycemic control, insulin use was
associated with a weight gain of a mod-
est 2.1 kgmore than on the oral regimen,
the rate of hypoglycemia requiring assis-
tance was modest (1% per year; ,10%
per year for nonsevere conﬁrmed hypo-
glycemia), and there was no evidence
of increased risk of malignancy or other
serious adverse events. Adding the expe-
rience from ORIGIN to previous observa-
tions, particularly UKPDS, it can be
argued that the evidence base for
insulin is better than that for any other
glucose-lowering agents, except perhaps
metformin.
Even so, it must be acknowledged
that although the safety and beneﬁt of
moderate doses of insulin in the long-
term are clear (7,9,10), the use of high-
dose insulin therapy, especially with
mealtime injections, for people with
obesity and severe insulin resistance
might still be associated with adverse
outcomes. Also, the evidence base
does not satisfactorily address the an-
swers to common questions that physi-
cians ask themselves, such as whether it
is time to start insulin or, alternatively,
whether other therapies should be
considered.
Another issue is what insulin and
what insulin regimen should be chosen,
perhaps bearing in mind the future need
Table 1—Summary of the evidence base for starting insulin in type 2 diabetes
Evidence type Evidence ﬁndings
Strong observational and randomized clinical trial evidence
Insulin secretory capacity deteriorates with time (5)
Insulin improves glycemic control in trials and in routine clinical
practice (3,9,13,14,16)
Improved glucose control improves HRQoL (12)
LADA phenotype is associated with early need for insulin therapy (28)
Randomized clinical trial evidence of variable quality
Outcomes of acute illness are improved if glycemic control is better (61)
Long-term medical outcomes are improved by better glycemic
control (7,10,62)
Glycemic control to ,53 mmol/mol (,7.0%) HbA1c is difﬁcult to
achieve and maintain with insulin (3,16)
Insulin is successful in combination with oral agents and
GLP-1RAs (49,63)
General knowledge and expert experience
Insulin treats and prevents ketoacidosis (64)
Severe hyperglycemia predisposes to infection (53)
Physician hesitancy in starting insulin therapy is a main barrier to
insulin use (4)
Patient preferences and views of injected therapies vary markedly (4)
Insulin therapy can be tailored rapidly to changes in need during acute
illness
Insulin has potential powerful anabolic effects (wound healing, etc.)
HRQoL, health-related quality of life.
1500 Insulin Therapy in People With Type 2 Diabetes Diabetes Care Volume 37, June 2014
of optimization associated with the pro-
gression of the condition, and consider-
ing potentially high-risk subgroups for
which speciﬁc tactics might be chosen.
Basal insulins offer simplicity in injection
frequency and ease of dose titration but
may not be adequate to address post-
prandial excursions (15,18). This is par-
ticularly true with further loss of islet
b-cell function, whence a mealtime +
basal regimen will be needed, some-
times with mealtime insulin introduced
meal by meal (16,19). Premixed insulins,
started once or twice daily and occa-
sionally increased to thrice daily, can
offer a simpler approach where meal-
time insulin is needed. However, premix
insulins lack ﬂexibility for dose adjust-
ment and limit calibration of doses be-
tween the mealtime and basal needs.
They also give a poorer basal insulin pro-
ﬁle at night and more risk of daytime
hypoglycemia compared with basal
alone if mealtime insulin is not needed
(20).
WHEN SHOULD INSULIN THERAPY
BE STARTED?
Indications for insulin therapy and when
to begin it are poorly deﬁned in guide-
lines and still subject to individual judg-
ment based on a wide range of opinion
(21,22). Personal beliefs and experi-
ence, familiarity with the use of the dif-
ferent insulin preparations and delivery
systems, individual preference, patient
needle phobia, concern about chronic
hyperinsulinemia, risk of hypoglycemia,
and difﬁculties in controlling body
weight are some of the many consider-
ations regarding insulin therapy (4,23).
Each one of these factors can be
weighted differently between doctors
and between people with diabetes.
The expert group proposed that one
way to rationalize the approach to insu-
lin treatment could be to consider some
clinical scenarios. These could be as fol-
lows: 1) the time of diagnosis or early
thereafter; 2) in the presence of other
emerging medical conditions; and 3) in
the course of routine ambulatory diabe-
tes management.
Time of Diagnosis or Early Thereafter
In speciﬁc circumstances, insulin may be
considered a potential ﬁrst line therapy
(Table 2 and Fig. 1) (24). Presentation of
diabetes with ketonuria, with or without
marked symptoms, should raise the
suspicion of type 1 diabetes, although
the possibility of accelerated lipolysis
and ketogenesis due to starvation also
deserves consideration. Ketoacidosis can
bepresent at the timeof diagnosis of type
2 diabetes, especially in the presence of
another metabolic stress (i.e., myocardial
infarction or infection or use of antiretro-
viral therapy). In such situations, immedi-
ate use of insulin is recommended and
sometimes mandatory.
However, more common is the pre-
sentation of marked hyperglycemia
with or without notable symptoms or
ketonuria or advanced comorbidities
(Fig. 1). Some guidelines suggest insulin
is indicated for HbA1c .69 mmol/mol
(.8.5%) at diagnosis (24). This approach
is not well substantiated by evidence,
but it clearly can help by reducing glu-
cose toxicity. Some evidence suggests
short-term insulin therapy might help
preserve b-cell mass, but this is proba-
bly still too speculative to inﬂuence clin-
ical practice decisions (25). More
substantial is evidence that restoration
of nearly normal glucose levels with
short-term administration of insulin at
the time of diagnosis can allow recovery
of b-cell function and improvement of in-
sulin sensitivity sufﬁcient to induce a clini-
cal remission, during which lifestyle efforts
either alone or with oral therapy canmain-
tain control for some time (26,27).
Insulin is usually needed when diabe-
tes is diagnosed in the context of an
acute medical event causing acute meta-
bolic deterioration, or in case of surgery or
any other invasive procedure, temporarily
or for longer term (Table 2 and Fig. 1).
Some oral agents may be contraindicated
in these situations, and insulin may be
used to provide rapid and reliable control
of the metabolic disturbance.
Lack of response or, even worse, fur-
ther deterioration of glycemic control in
spite of lifestyle modiﬁcation and/or
glucose-lowering agents should prompt
consideration of the diagnosis of latent
autoimmune diabetes in adults (LADA)
(28). Measurement of glutamic acid de-
carboxylase (GAD) antibodies can con-
ﬁrm the diagnosis, but usually the
clinical phenotype of low BMI, low waist
circumference, little or no dyslipidemia
(high triglycerides/low HDL cholesterol),
Table 2—“Algorithm” for starting/shifting insulin therapy
1. Is there an acute need?
c Ketones (in absence of starvation)/ketoacidosis/dehydration
c Marked hyperglycemia (without carbohydrate/calorie abuse)
c Acute medical event with actual/potential decompensation
c Marked hyperglycemia with uncertain near-future environment (foreign travel)
→Strong immediate needdpersuasive advice may be needed
2. Within ;2 years of diagnosis?
c LADA phenotype or secondary pancreatic phenotype
c Presence of GAD antibodies/low BMI/waist circumference/no dyslipidemia
c Deterioration in glucose control in 6–24 months despite uptitration of multiple oral agent
therapy
c Concomitant disease: pancreatitis, hepatic cirrhosis, chronic steroid therapy, relapsing
inﬂammatory disease, antirejection therapy, other
→Discuss that insulin therapy will be inevitable or make medical self-management easier
and saferdﬁrm recommendation to start now
3. Taking one to four other glucose-lowering therapies and not to target (HbA1c.58 mmol/mol
[.7.5%])?
c No other explanation for change in glucose control
c Progression of hyperglycemia despite oral agent uptitration or neglected glucose control:
c on three or more oral agents/GLP-1RA with HbA1c above 58 mmol/mol (7.5%)
c on two or more or more oral agents/GLP-1RA with deterioration of .8 mmol/mol
(0.7%) HbA1c since last seen without explanation
c on one or more oral agent(s) with deterioration.11 mmol/mol (1.0%) HbA1c since last
seen without explanation
c Previous patient education given and personal lifestyle input unlikely to improve
c Patient preference for injectable natural hormone to drug
→Discuss longer-term beneﬁts of blood glucose control to target and efﬁcacy (and
tolerability issues) of insulin
o Consider alternative of a GLP-1RA (in particular if obese and happy to tolerate GI
symptoms)
o With caution if hypoglycemia experienced on sulfonylureas
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and lack of family history of diabetes is
sufﬁcient to raise suspicion. In these pa-
tients, insulin therapy can rapidly re-
store glycemic control and possibly
slow the decline of insulin secretory
function (28).
Presence of Other Nonacute Medical
Conditions
People with a LADA-like phenotype
(lean, relatively young, and no family
history of diabetes) but without GAD
antibodies could have secondary pan-
creatic diabetes due to acute or chronic
pancreatitis or, more rarely, pancreatic
cancer (Table 2). Other conditions po-
tentially associated with the need for
early insulin therapy include hepatic
cirrhosis (29). In this setting, mealtime
insulin is often needed to control post-
prandial hyperglycemia. People using
glucocorticoid therapy, especially when
taken intermittently at high dosage,
quite often beneﬁt from the power and
ﬂexibility of insulin therapy. Starting in-
sulin can also ease blood glucosemanage-
ment during use of immune-suppressant
therapy or antiretroviral therapies.
Ambulatory Diabetes Management
The more typical question is when to
advise starting insulin for people taking
two or three (or sometimes one or four)
oral agents. Critical questions at this
point are the level of glycemic control,
rate of progression of hyperglycemia,
available alternatives, and personal
preferences (23). These will be modu-
lated by concerns about and perhaps
past experience with hypoglycemia
(e.g., from prior use of a sulfonylurea),
morbid obesity, concomitant disease,
and life expectancy, all of which may in-
ﬂuence the choice of therapy and per-
sonal glycemic targets (23).
Earlier and more rapid progression of
hyperglycemia, perhaps evidenced by a
more rapid need for multiple oral
agents, suggests greater need for insulin
(Table 2, item 3 and Fig. 1). For an in-
dividual who appears eligible for a “typ-
ical” glycemic target, such as HbA1c,53
mmol/mol (,7.0%), it is reasonable to
start thinking about insulin if HbA1c is
.58 mmol/mol (7.5%). If HbA1c is .64
mmol/mol (8.0%), an additional oral
agent will generally not be effective in
reaching the target level unless lifestyle
education has previously been ne-
glected or adherence to lifestyle mea-
sures might improve, and thus insulin
becomes a more attractive option.
Because oral agents have limited efﬁ-
cacy, if glucose control is deteriorating
rapidly, they may not be able to over-
take the rate of deterioration, and in
that case, insulin therapy may be
preferable.
Individual preference may be to delay
insulin by starting another treatment.
When this is done, it is desirable to ad-
vise the patient that the plan will be
reevaluated in 4–6 months. If glycemic
control is then unacceptable, insulin
should be recommended, usually with
continuation of some of the other
therapies.
The stepped algorithm for use of di-
abetes therapies with time does seem to
get ever more complex, as the range of
options increases with newer classes of
glucose-lowering medications (24). One
advantage of insulin therapy is often for-
gotten here, namely that since it is
inevitable for the majority of individu-
als, starting it early, when people are
only on one or two oral agents, consid-
erably simpliﬁes further management.
Essentially recurrent decisions and as-
sessments over which other class or in-
dividual medication to use are avoided
for the most part, along with the prob-
lems ofmonitoring success and eventual
“failure” of each of those other agents.
Since however many medications are li-
censed in at least some major markets
for combination with insulin therapy,
starting insulin does not preclude the ad-
dition of dipeptidyl peptidase-4 (DPP-4)
inhibitors, glucagon-like peptide-1 re-
ceptor agonists (GLP-1RAs), thiazolidine-
diones, or sodium/glucose cotransporter
2 (SGLT2) blockers, should a speciﬁc in-
dication become clear while insulin is
being used.
Figure 1—Summary of the use of insulin and other glucose-lowering approaches over the course
of time in a person with type 2 diabetes. ause of insulin may be temporary. BP, blood pressure;
OGLDs, oral glucose-lowering drugs; TG, triglyceride.
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CONSIDERATION OF OTHER
OPTIONS
The decision to start insulin therapy will
not usually be taken in isolation. Indeed
rather than “should insulin be started?”,
the most appropriate question is usually
“which of a series of options is most
appropriate for this person already on
treatment but needing better blood glu-
cose control?” In the above discussion,
we consider situations in which insulin
might be started, but in only a few (e.g.,
ketoacidosis or other acute metabolic
disturbance or prospect thereof) will in-
sulin be mandatory, although in many
cases (pancreatic diabetes, suspected
LADA, or intermittent steroid therapy),
it can also be the simplest approach to
manage in the medium-term (Fig. 1).
Further Lifestyle Advice and Oral
Agents
At the time of diagnosis, an oral agent
can have quite prominent glucose-
lowering effects, especially when initi-
ated along with lifestyle instruction/
modiﬁcation. The rapid action of the sul-
fonylureas can help achieve a rapid im-
provement of glycemic control (30), and
the slower onset of action by metformin
can similarly lead to an 11–22mmol/mol
(1.0–2.0%) reduction of HbA1c, assisted
by reversal of glucose toxicity. As noted
above, guidelines generally recommend
insulin instead if HbA1c is very high,
and this would be particularly true if
lifestyle already seemed good or there
was suspicion of LADA or pancreatic di-
abetes (Fig. 1).
In continuing ambulatory care, with
established oral therapy, appropriate
lifestyle advice will most often already
have been given, even if full applica-
tion of that advice was problematic to
the individual. In these circumstances,
delaying insulin or other effective ther-
apy while expecting signiﬁcant further
change is unwise. However, when the
patient has had limited or no prior edu-
cation and instruction, further lifestyle
counseling in conjunction with even a
moderately effective additional therapy
can achieve good results.
Otherwise, all oral agents have lim-
ited efﬁcacy in the setting of failure of
one or more prior oral therapies. The
reduction in HbA1c 12 months after
supplementing prior oral therapy
with a sulfonylurea, metformin, or a
thiazolidinedione is no more than 5–11
mmol/mol (0.5–1.0%) from a baseline of
;64 mmol/mol (8.0%), so very few peo-
ple can be expected to get to target
by adding these agents alone (31,32).
DPP-4 inhibitors are probably even less
effective and SGLT2 blockers no more
effective. At higher HbA1c, failure to at-
tain target levels will be inevitable with-
out other change. In all cases, reassessment
of glycemic control after 4–6 months is
desirable.
GLP-1RAs
An appropriate option to be considered
in the ambulatory situation where insu-
lin is also a possible choice is a GLP-1RA.
This does not apply to other circumstan-
ces where insulin might be started, such
as more extreme hyperglycemia, other
acute medical illness, or for LADA phe-
notype or secondary pancreatic diabe-
tes. Advantages compared with insulin
might include lack of need for dose titra-
tion after the ﬁrst few weeks, less fre-
quent self-monitoring of glucose, lower
risk of hypoglycemia, and a favorable ef-
fect on body weight (33). Disadvantages
are nausea and sometimes vomiting and
other gastrointestinal side effects, as well
as uncertainty over increased risk of pan-
creatitis and indeed other long-term ef-
fects. The efﬁcacy of these agents is well
documented even when compared with
basal insulin treatment, although the in-
sulin doses used in such studies often
seem suboptimal (34,35). It is noteworthy
that despite frequent reluctance to begin
any injected therapy, in both clinical stud-
ies and routine practice, insulin is more
likely to be continued after initiation than
GLP-1RAs.
The GLP-1RA advantage of not being
associated with weight gain and very of-
ten leading to weight loss is of particular
relevance given the frequency of obesity
among type 2 patients. Weight gain as-
sociated with insulin therapy ranges be-
tween 0 and 5 kg in different studies,
depending on the baseline HbA1c and
the circumstances in which insulin is
started (3,7,16). In studies in routine
care, the gain of weight is greatest in
people who are less obese (36). Al-
though weight gain associated with in-
sulin therapy is widely seen as an
argument against using insulin, clear ev-
idence for negative medical outcomes
of weight gain is lacking.
Nonetheless, the favorable effect of
GLP-1RAs on weight is attractive to
providers and patients alike. Preliminary
data suggest that this effect is even
more apparent for people who have
BMI .30.0 kg/m2 (37,38). Therefore,
for an obese person with diabetes not
maintaining control targets on lifestyle
plus oral agents, the use of a GLP1-RA
before introducing insulin therapy may
be logical. Obese people on treatment
for diabetes are rarely able to fully
implement a desirable change of
lifestyle, but on occasion, effective
weight-reducing therapy can provide a
stimulus to further change. However, in
general, people with higher HbA1c levels
will have less b-cell function, which is
needed for GLP-1RA therapy to be fully
effective in lowering glucose. Therefore,
although glucose reductions are greater
with the longer-acting GLP-1RAs (lira-
glutide and once-weekly exenatide)
than with oral agents, it is unreasonable
to expect targets to be attained in a ma-
jority of people from a baseline HbA1c of
.69 mmol/mol (8.5%) unless further
lifestyle change is made (33).
Combination therapy of insulin and
GLP-1RAs appears effective and may
gain the glucose-lowering advantages
of both while controlling body weight
and reducing risk of hypoglycemia (39).
Preliminary evidence suggests that one
route to injectable therapy might in-
volve starting the two in combination,
even if this means limited titration of
insulin doses initially (40). Meanwhile,
the addition of either to the other may
be clinically advantageous.
Bariatric Surgery
Bariatric surgery has consistently dem-
onstrated signiﬁcant improvement in
blood glucose control compared with
standard or intensive medical therapy
for people with diabetes, patients with
BMI .35.0 kg/m2, and sometimes the
less obese (41–43). Efﬁcacy has been
demonstrated across a wide range of
age and diabetes duration, comorbidities,
or need for current glucose-lowering
therapies including insulin. Weight
loss after bariatric surgery can be very
marked (average of 25 kg or more) and
the need for glucose-lowering and
blood pressure–lowering medications
reduced. However, these procedures
appear to be less effective in diabetes
when BMI is ,35.0 kg/m2, when the
duration of diabetes is .4 years, or
when fasting C-peptide levels are
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,0.96 nmol/L (,2.9 ng/mL) (44,45).
Older people appear likely to have
greater risks associated with these sur-
gical procedures (46,47).
This suggests that bariatric proce-
dures deserve consideration for obese
but otherwise vigorous people with
type 2 diabetes who have disappointing
responses to usual glucose-lowering
therapies. That bariatric surgery is of-
fered to obese people without diabetes
tells us that people with diabetes might
beneﬁt if obesity itself is a sufﬁcient
indication. For obese people with dia-
betes already taking insulin, whose
continuing weight gain appears to be
preventing attainment of glucose con-
trol, bariatric surgery may be an option
worth considering. However, due to lack
of long-term follow-up of outcomes,
bariatric surgery does not at the present
time seem appropriate as an alternative
to insulin and other validated therapies
for hyperglycemia but rather as a sup-
plement to them in controlling obesity
(48).
A GUIDE FOR THE DECISION TO
START INSULIN
Most clinicians do not think algorithmi-
cally when managing clinical conditions
and advising people with diabetes. They
often prefer to follow a patient-led
agenda, and individuals will highlight
their problems and preferences for sol-
utions in quite different ways. As a
result, a simple algorithm for starting
insulin is not feasible. However, it is pos-
sible to provide a checklist thatmay help
to guide the clinician-patient interaction
to ensure that decisions occur in a logi-
cal way, and importantly without miss-
ing the opportunity to obtain relevant
information (Table 2).
The ﬁrst consideration might be to
assess whether an acute need is pres-
ent, although usually that will be obvi-
ous. At diagnosis, other referral, or
when admitted for whatever reason as
an in-patient, the presence or absence
of marked hyperglycemia, weight loss,
ketones, ketoacidosis, or dehydration
must be ascertained. If marked hyper-
glycemia alone is present, is there an
acute precipitating factor, and if not, is
there any prospect that glycemic control
can be restored by lifestyle change? Is
the patient in a risky or uncertain envi-
ronment? In these cases, there may be a
strong, immediate need, and persuasive
advice to consider insulin may be appro-
priate (Fig. 1).
Then, consider whether the LADA
phenotype, pancreatic diabetes, or he-
patic cirrhosis may be present. GAD an-
tibody levels may be requested or be
available. Deterioration in glucose con-
trol over the next 6–24 months despite
uptitration of oral agents is perhaps the
most important indicator. That should
lead to a discussion that insulin therapy
is inevitable; in time, it will make man-
agement easier and safer.
In longer-term diabetes manage-
ment, has hyperglycemia progressed
rapidly or glucose control been ne-
glected recently? Here the discussion in-
cludes alternatives and the likely
scenarios for such therapies. This needs
discussion of the effects and tolerability
of insulin, including hypoglycemia, risks
of weight gain, perhaps together with
the eventual inevitability of the need
for insulin. Whether the introduction
of insulin will affect an individual’s abil-
ity to drive or maintain other key life
activities, especially related to occupa-
tion, should be explored. Also consider
alternatives, including GLP-1RAs, and
their attractive features and problems.
It is important not to present insulin as
indicative of failure or a punishment.
At any stage, the preferred option
should be negotiated, with in most
cases a contingency planning option if
personal targets are not met in a period
ofmonths. A further issue here concerns
continuing of oral agent therapy, or
more speciﬁcally sulfonylureas, as met-
formin is usually continued. If a regimen
including mealtime insulin is chosen (in-
cluding premixes), sulfonylureas are
usually stopped to avoid compounding
the hypoglycemia risk, but there is less
certainty when beginning basal insulin
alone where at least temporarily glu-
cose control will deteriorate without
rapid insulin dose titration (49). If hypo-
glycemia does occur on the combination
of insulin and a sulfonylurea, clinical ex-
perience is that the sulfonylurea should
be stopped rather than insulin doses re-
duced. Thiazolidinediones are also often
stopped when starting insulin as the
edema and weight gain risks are com-
pounded, but may be worth continuing
in the very obese insulin-insensitive in-
dividual. A DPP-4 inhibitor can be con-
tinued, although perhaps to little
beneﬁt.
FURTHER OPTIMIZATION AND
PERSONALIZATION OF INSULIN
THERAPY
After systematic application of lifestyle,
oral agent, and injectable therapies for
type 2 diabetes, some patients remain
unable to achieve or maintain sufﬁcient
glycemic control to avoid the onset or
progression of glycemia-related compli-
cations. Speciﬁcally, even after adoption
of initial lifestyle changes, trying ade-
quate courses of oral glucose-lowering
agents, starting and optimizing insulin
therapy, and consideration of GLP-
1RAs, a signiﬁcant proportion of people
have HbA1c levels .53 mmol/mol
(7.0%). In the population enrolled in
the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial, which
had both 10 years average duration of
diabetes and high cardiovascular risk,
about 25% of individuals assigned to in-
tensive glucose-lowering therapy were
unable to maintain HbA1c levels ,52
mmol/mol (7.0%) (50). The further ob-
servation that this subgroup, in which
insulin therapy was expected to be op-
timized, had both higher risk of hypogly-
cemia and higher risk of all-cause
mortality has focused attention on the
clinical dilemmas posed by such people.
A general conclusion is that such people
need further consideration of the aims
in personalizing their therapy regimens,
with the goal of balancing the gains and
losses in risk and quality of life from
medications. The difﬁculty in translating
this conclusion into practical clinical
guidance is well recognized and was re-
ﬂected by discussions at this expert fo-
rum. Several questions were addressed
to focus these discussions.
How Can This Category of Patients Be
Deﬁned and Identiﬁed?
An analysis of data from ACCORD sought
to identify baseline characteristics that
were associated with excess mortality
accompanying intensive as compared
with standard treatment. Just three clin-
ical predictors emerged: baseline levels
of HbA1c .69 mmol/mol (.8.5%), any
prior history of neuropathy, and current
aspirin use (51). It is possible the study
was too short to have the power to iden-
tify other predictors. Poor glycemic con-
trol at entry to the study seems likely to
have indicated preexisting difﬁculty
with glycemic management, and this in
itself may have been associated with
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other factors driven out by the multivar-
iable analysis, such as comorbidities.
The other “historical” ﬁndings (neurop-
athy and aspirin) imply the presence of
already known or suspected complica-
tions of diabetes, microvascular and
macrovascular. In addition, a subse-
quent analysis of on-treatment experi-
ence in ACCORD indicated that inability to
reduce HbA1c by at least by 5 mmol/mol
(0.5% units) from the baseline level with
an intensive treatment regimen corre-
lated with risk of excess mortality (50).
Together these observations suggest
that high medical risk (among people
already known to have high cardio-
vascular risk) accompanying intensive
therapy can be identiﬁed quite early,
either by ﬁnding poor glycemic control
before treatment optimization is at-
tempted or by observing a disappoint-
ing response to the ﬁrst efforts to
improve treatment. However, as noted
above, many people in poor glucose
control have a very good response to
insulin therapy, so it is important to
distinguish difﬁculty in obtaining con-
trol from neglect of good control.
Stated otherwise, people who have lit-
tle success at ﬁrst are likely to have
difﬁculty later and are at high risk of
diabetes-associated and comorbid ad-
verse outcomes.
Where response to initial insulin ther-
apy is poor, or is initially satisfactory but
then deteriorates with time due to pro-
gressive islet b-cell failure, the multi-
tude of insulin types do offer various
ways to improve clinical results. How-
ever, where basal insulin alone is being
used, a ﬁrst action is to ensure the dose
has been titrated to usual fasting plasma
glucose targets. Use of more extended
self-monitoring can then establish the
pattern of daytime and nocturnal glu-
cose levels, allowing an informed deci-
sion as to the addition of one or more
mealtime insulin doses. If simplicity but
less ﬂexibility is judged desirable, a
switch to premix insulin may be pre-
ferred. Coprescription of a GLP-1RA
(see GLP-1RAs) is another option.
How Should Glycemic Targets Be
Altered?
The simplest and most often discussed
modiﬁcation of usual therapy for people
thought to be at high risk is to modify
the HbA1c target range. Instead of seek-
ing HbA1c ,53 mmol/mol (,7.0%),
higher-risk individuals are commonly
advised to aim for between 53 and
64 mmol/mol (7.0 and 8.0%) (23). Al-
though this was the target range for
the standard treatment arm in ACCORD,
evidence arguing that this range is al-
ways the most appropriate remains lim-
ited. For example, individuals with
limited life expectancy and having
HbA1c of 75–86 mmol/mol (9.0–10.0%)
probably have little to gain from stren-
uous efforts to reduce this value to,64
mmol/mol (8.0%). Similarly, people with
serious medical illnesses requiring com-
plex treatments, such as those with
cancer undergoing treatment with cyto-
toxic regimens, might not need to seek
even a relaxed HbA1c target range (23).
However, very high HbA1c levels (per-
haps .86 mmol/mol [.10.0%]) are as-
sociated with an acute risk of increased
infection and vascular thrombosis as
noted above (52,53), as well as tired-
ness, weight loss, and inconvenient
polyuria.
How Can Therapeutic Approaches Be
Revised?
Even when individuals with conditions
or circumstances allowing exemption
from speciﬁc glycemic targets are re-
moved from discussion, a sizable group
of people who have no apparent reason
not to attainHbA1c in the53–64mmol/mol
(7.0 to 8.0%) range remains. Insulin ther-
apy is often said to be unlimited in its
capacity to lower glucose levels, but in
practice, even very high prescribed
doses sometimes yield results that
fall short of expectations (54). The un-
derlying causes of failure of usual treat-
ments are undoubtedly numerous, and to
understand them calls for further effort
to identify the personal characteristics of
each person that may prove relevant
(Table 3). In many cases, progressive
obesity, as a marker for high calorie in-
take and insulin resistance, identiﬁes a
metabolic challenge that resists success
even when ample insulin is delivered to
tissues. Other medical conditions may
be important. Examples include unrec-
ognized Cushing syndrome or a genetic
or acquired disorder of extreme insulin
resistance.
For some people, psychological fac-
tors may interfere with adherence to
the regimen or lead to very poor deci-
sions on the timing and dosage of insu-
lin. Obtaining accurate information
about actual use of insulin and other
medications, independent of what has
been prescribed, can be very challeng-
ing. For others, environmental pres-
sures, including ﬁnancial constraints,
family or work-related conﬂict, or social
isolation, may prove to be central
factors.
Only occasionally will addition of a
new medication or change of dosage
of existing ones then solve the problem
at hand, but consideration of addition of
GLP-1RAs, DPP-4 inhibitors, pioglita-
zone, or SGLT2 blockers is appropriate
in some cases (licensed indications vary
by market) (39,55,56). In general, all
these further lower glucose in the
short-term, but this effect may be coun-
tered by insulin dose reduction with
time. Medications such as GLP-1RAs
and SGLT2 blockers can reduce the ef-
fects of insulin onweight gain. Pioglitazone
can sometimes have dramatic effects on
very high insulin dose requirements, but
Table 3—Dealing with problems when on insulin therapy
1. Failure to improve glucose control after adequate dose titration
c Presence of comorbidities, prior control difﬁculties, occurrence of hypoglycemiadhigher-
risk person for amelioration of glucose control targets?
c Adherence and acceptance of insulin issues?
2. Excessive weight gain
c Implies high calorie intakedreview lifestyle issues and consider a trial of adding GLP1-RA
or SGLT2 inhibitor therapy
3. High insulin dose requirement in the markedly obese person
c Consider trial of adding a thiazolidinedione
4. Severe recurring hypoglycemic events
c Nocturnaldconsider using long-acting insulin analog, timing of basal insulin injection,
possibility of hepatic cirrhosis or steroid therapy with need for predominant meal-time
insulin therapy
c Daytimedconsider contribution of meal-time insulin (reduce or move to basal-only
regimen) or lifestyle issues (missed meals or alcohol)
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at the expense of further weight gain.
These combinations can be very expen-
sive or of unproven safety and so cur-
rently seem appropriate for a minority
of insulin takers (57).
When evidence or suspicion of re-
peated hypoglycemia is present, a
change of insulin type or distribution
might be beneﬁcial. For people using
NPH as basal insulin, the long-acting in-
sulin analogs (glargine, detemir, and de-
gludec) offer evidence-based reduction
in risk of nocturnal hypoglycemia
(13,14,58,59). For people with daytime
hypoglycemia when using sulfonylurea
or mealtime insulin together with basal
insulin, consideration can be given to
reducing the dosage of these agents or
stopping them entirely while continuing
basal insulin. Substituting a shorter-
acting GLP-1RA for mealtime insulin is
another option (39). Appropriate life-
style adjustments to limit hypoglycemia
caused by insulin may also be helpful.
Exploring individual factors and their
interactions lies at the center of person-
alized treatment and poses a more dif-
ﬁcult challenge in this setting than at the
time of starting standard treatments for
an unselected population of patients
(60). Personalized use of insulin and
other therapies by people who have al-
ready demonstrated little success with a
more generic approach requires time,
expertise, and motivation.
SUMMARY AND CONCLUSIONS
The group’s discussion noted that insu-
lin has been used longer than any other
medication for treating diabetes, and
the body of evidence supporting a favor-
able balance of beneﬁts to risks of its use
continues to grow. Some large, long-
term clinical trials, including the UKPDS,
Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interven-
tions and Complications (DCCT/EDIC),
and ORIGIN, have shown that both mi-
crovascular and cardiovascular beneﬁts
can be obtained. Initiation of insulin
therapy is appropriate at various stages
of diabetes, depending on the clinical
circumstances of each case. Use as the
ﬁrst form of pharmacotherapy is needed
when the diagnosis of diabetes is made
at a time of acute illness or severe met-
abolic decompensation, or when a form
of diabetes characterized by marked in-
sulin deﬁciency is present. Later, when
lifestyle intervention and oral therapies
are no longer fully successful, insulin is
usually the most desirable ﬁrst injected
therapy, but GLP-1RAs should be consid-
ered in some cases because of their
unique ability to limit weight gain and
reduce glucose with little risk of hypo-
glycemia. Some large interventional
studies, notably ACCORD, suggest that
subgroups with less potential beneﬁt
and higher risk of hypoglycemia and
other complications of insulin use should
be identiﬁed and managed differently.
Although evidence remains incomplete,
a history of established complications of
diabetes, long-term difﬁculty with glyce-
mic control, and a poor response to re-
cent efforts to intensify control all argue
for adjustment of either the HbA1c target
range or therapeutic tactics, or both.
Further information on the use of com-
binations of therapies, especially includ-
ing the newer agents such as GLP-1RAs,
DPP-4 inhibitors, and SGLT2 blockers, for
this problematic subgroup of patients is
needed. Finally, this discussion clearly
demonstrates that despite its long
history, much remains to be learned
about the best ways to use insulin ther-
apy, which continues to be centrally im-
portant in the management of type 2
diabetes.
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